Compare NCNO & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCNO | IRON |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.4B |
| IPO Year | 2020 | N/A |
| Metric | NCNO | IRON |
|---|---|---|
| Price | $23.38 | $93.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 12 |
| Target Price | $33.40 | ★ $108.83 |
| AVG Volume (30 Days) | ★ 2.2M | 533.0K |
| Earning Date | 12-03-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $586,485,000.00 | N/A |
| Revenue This Year | $10.88 | N/A |
| Revenue Next Year | $8.53 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.14 | N/A |
| 52 Week Low | $18.75 | $30.82 |
| 52 Week High | $40.29 | $97.12 |
| Indicator | NCNO | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 35.75 | 62.09 |
| Support Level | $24.12 | $87.18 |
| Resistance Level | $27.50 | $96.18 |
| Average True Range (ATR) | 0.98 | 3.86 |
| MACD | -0.03 | -0.36 |
| Stochastic Oscillator | 0.93 | 63.81 |
Ncino Inc is a provider of cloud-based software for financial institutions. Its software solution digitizes, automates, and streamlines inefficient and complex processes & workflows and utilizes data analytics & artificial intelligence that enables financial institutions to onboard new clients, make loans, and manage the entire loan life cycle, open deposits, and other accounts, and manage regulatory compliance. It also offers professional services, including configuration & implementation, training, and advisory services. The company generates the majority of its revenue from subscription services. The company caters to financial institutions, enterprise banks, regional banks, community banks, and credit unions. The vast majority of its revenue comes from the United States.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.